Early Stage Considerations for the Manufacture and Delivery of Vaccines - Stevanato Group
search img
Early Stage Considerations for the Manufacture and Delivery of Vaccines - Stevanato Group
Home - Integrated solutions for pharma & healthcare - Stevanato Group > News & Events - Stevanato Group > Webinars - Stevanato Group > Early Stage Considerations for the Manufacture and Delivery of Vaccines - Stevanato Group

Early Stage Considerations for the Manufacture and Delivery of Vaccines

16 December 2020

Stevanato Group, IQVIA and NRL Enterprise Solutions will present a Webinar on:

Early Stage Considerations for the Manufacture and Delivery of Vaccines

Webinar Details:

  • Date: Wednesday, December 16th 
  • Time: 10.00 am CET / 5.00 pm UTC+8
  • Duration: 1 hour
  • Language: English


Register your Virtual Expo Account and join our webinar!

Webinar abstract:

Packaging and delivery systems for vaccines are continually evolving as complexity increases, and the past six months especially have placed a spotlight on the readiness and requirements of pharma packaging companies to support the distribution and delivery of a potential COVID-19 vaccine. To extract as much value as possible from R&D, solutions must be developed with the end goal in mind. Selecting the most suitable primary packaging options for drug products is one of the most crucial considerations in the drug development process, and getting this wrong can result in additional costs and challenges later down the line. This webinar will examine packaging solutions that de-risk the drug development process for vaccines, manage costs, and facilitate speed to market.

Key Learning Objectives:

  • Market outlook for vaccine development and packaging solutions
  • COVID-19 vaccine development in focus
  • Road-mapping the selection of primary containers - formulation considerations and filling technologies
  • How can cost, value, and scale be balanced?

Why Attend?

  • Get the complete overview of the global packaging landscape for vaccines in 60 minutes
  • Hear about efforts for manufacturing at scale
  • Learn about innovative primary packaging solutions coming to market which can save costs and improve speed to market
  • Hear from speakers who really understand what’s driving the industry forward

About the speakers:

Daniel Martinez Photo
Daniel Martinez Photo

Daniel Martinez

Product Manager Syringes, Add-on Components, and Analytical Services, Stevanato Group

Daniel Martinez is the Product Manager for Syringes, Add-on Components, and Analytical Services at Stevanato Group since 2017. In his role, he is responsible for the development and go-to-market strategy of syringes and add-on components as well as analytical services. He has experience in different aspects and functions such as production, technical liaison, quality, project management, and sales. He holds a bachelor’s degree in Mechatronics Engineering from the Instituto Tecnológico y de Estudios Superiores de Monterrey. Prior to joining Stevanato Group, Mr. Martinez has been covering commercial and operational roles in international companies dedicated to primary packaging.

Yasemin Karanis Photo
Yasemin Karanis Photo

Yasemin Karanis

Senior Consultant, IQVIA

Yasemin is a Consultant in the European Thought Leadership team based in IQVIA’s London office. Her primary areas of focus are; trends in innovative launches, drug delivery and formulations as well as the oncology market with an emphasis on commercial trends. She has presented and moderated panels on these subjects in a variety of conferences. Yasemin holds a Masters in Cancer Research and a Bachelor of Science degree in Biomedical Sciences both from Newcastle University. Prior to her role in Thought Leadership, Yasemin was part of the Real-World Insights – Global Oncology team where she worked on the co-ordination and set-up of reports focusing on various cancers.

Kristopher Howard Photo
Kristopher Howard Photo

Kristopher Howard

Managing Director, NRL Enterprise Solutions

Kris is a vaccines and pharmaceutical consultant for organizations such as UNIDO, GIZ and WHO as well as global and LMIC vaccine/pharma companies. His work focuses on enabling mid-sized biotech and pharma firms to accelerate their growth through a mix of current facility operations optimization, planning for new facilities and helping them to secure strategic production partnerships. He is the author of three reports on vaccine manufacturing as part of an ongoing project conducted by UNIDO, WHO and AVMI. In his former role at Merck & Co. Inc (MSD), Kris evaluated and implemented local vaccine and pharma technology transfer deals in LMIC countries to facilitate MSD’s global expansion plans. Prior to this, he was part of MSD’s team responsible for designing, constructing, starting up and optimizing production facilities around the world. In this role he worked on new vaccine facility projects ranging in size from $15M to $300M. During his career he has worked extensively in the US, Latin America, Africa and Europe.